Page last updated: 2024-08-21

pyrazines and Diffuse Mixed Small and Large Cell Lymphoma

pyrazines has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 58 studies

Research

Studies (58)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	32 (55.17)	29.6817
2010's	25 (43.10)	24.3611
2020's	1 (1.72)	2.80

Authors

Authors	Studies
Yaqub, F	1
Banerjee, SK; Das, BC; Das, S; Evans, T; Kambhampati, S; Karki, R; Schinke, C; Thapa, P; Van Veldhuizen, P; Verma, A; Weiss, LM	1
Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM	1
Chauncey, T; Deauna-Limayo, D; Dong, Z; Liu, D; Pilz, R; Wang, HY; Wang-Rodriguez, J; Yan, M; Zhao, F	1
Evens, AM; Gordon, LI; Helenowski, I; Lossos, IS; Millenson, M; Rosen, ST; Smith, MR; Winter, JN	1
Kato, H; Kinoshita, T	1
Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A	1
Batalo, MS; Bose, P; Grant, S; Holkova, B	1
Abella-Dominicis, E; Barr, PM; Cheson, BD; Di Paolo, J; Dreiling, LK; Friedberg, JW; Greenwald, DR; Hawkins, MJ; He, J; Hu, J; Joshi, A; Lee, H; Liem, AK; Mclntyre, RE; O'Brien, SM; Reddy, A; Saylors, GB; Spurgeon, SE	1
Czuczman, MS; O'Connor, OA	1
Cheson, BD	2
Acharya, M; Britten, CD; Chan, K; Cohen, N; Dudov, A; Fuloria, J; Gabrail, N; Nemunaitis, J; Quinn, DI; Yee, L	1
Delmonte, A; Ghielmini, M; Sessa, C	1
Balasubramanian, S; Bhalla, S; Buggy, J; David, K; Evens, AM; Gordon, LI; Mauro, L; Miller, R; Prachand, S; Sirisawad, M	1
Hamlin, P; MacGregor-Cortelli, B; Moskowitz, CH; Muzzy, J; O'Connor, O; Schenkein, DP; Straus, D; Trehu, E; Wright, J; Zelenetz, AD	1
Bargetzi, M; Heizmann, M; Kotrubczik, N; Moosmann, P; Wernli, M	1
Cohen, LJ; Humphreys, BD; Laubach, JP; Rennke, HG	1
Rummel, M	1
Cheng, B; Cheung, YK; Lee, SM	1
Jiang, C; Yang, XG	1
Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z	1
Dreyling, M	1
Basak, GW; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W	1
Dalal, N; Kozolff, M; Nabhan, C; Starr, A; Tolzien, K; Villines, D	1
Bollard, CM; Buglio, D; Derenzini, E; Illés, A; Ji, Y; Jóna, A; Khaskhely, N; Medeiros, LJ; Shafer, JA; Younes, A	1
Gotoh, K; Ito, Y; Iwata, S; Kamakura, M; Kawada, J; Kimura, H; Nishiyama, Y; Saito, T	1
Feng, H; Girgis, S; Hellmann, A; Louw, VJ; Patel, H; Rule, S; Shpilberg, O; Skee, DM; van de Velde, H; Walewski, J	1
Arcila, M; Gerecitano, J; Gonzalez, C; Gounder, S; Lin, D; McDonald, A; Mulligan, G; O'Connor, OA; Ogilvie, S; Teruya-Feldstein, J; Zhang, Z; Zheng, J	1
Feldman, T; Goy, A; Mato, AR	1
Cilley, J; Evens, AM; Gallot, L; Gordon, LI; Larson, A; Patton, D; Rademaker, A; Roy, R; Spies, S; Variakojis, D; Winter, JN	1
Ghielmini, M; Stathis, A	1
Argnani, L; Baccarani, M; Ballerini, F; Broccoli, A; Casadei, B; Derenzini, E; Fabbri, A; Gandolfi, L; Guarini, A; Merla, E; Pavone, V; Pellegrini, C; Puccini, B; Quintini, G; Quirini, F; Stefoni, V; Vigliotti, ML; Zinzani, PL	1
Jäger, U	1
Reddy, GK	1
Gilles, F; Goy, A	1
O'Connor, OA	1
Adams, J; Choi, E; Dumetrescu, O; Esseltine, D; Hamlin, P; MacGregor-Cortelli, B; Moskowitz, C; Muzzy, J; O'Connor, OA; Portlock, C; Schenkein, D; Straus, D; Stubblefield, M; Trehu, E; Wright, J; Zelenetz, AD	1
Chaudhary, PM; Matta, H	1
Dalton, WS; Holle, L; Jung, L	1
Davidson, T; Schwartz, R	1
Anderson, KC; Hideshima, T; Mitsiades, CS; Mitsiades, N; Richardson, PG	1
Zelenetz, A	1
Orlowski, RZ	1
Jaehde, U; Scheulen, ME; Simons, S	1
Coleman, M; Furman, RR; Leonard, JP	1
O'Connor, OA; Paoluzzi, L	1
Bohlius, J; Engert, A; Hülsewede, H; Kober, T	1
Esseltine, D; MacGregor-Cortelli, B; Muzzy, J; O'Connor, OA; Schenkein, D; Scher, H; Slovin, S; Stubblefield, MD; Wright, J	1
Nguyen, CA; Romaguera, J; Wang, M; Zhang, L; Zhou, Y	1
Boral, A; Busam, K; Esseltine, D; Gerecitano, J; Gonen, M; Goy, A; MacGregor-Cortelli, B; Neylon, E; O'Connor, OA; Sachs, D; Schenkein, D; Teruya-Feldstein, J; Wright, J	1
Ballestrero, A; Brossart, P; Grünebach, F; Nencioni, A; Patrone, F	1
Jin, J; Li, Y; Meng, H; Qian, J; Tong, Y	1
Antonio, S; Daniele, V; Enrico, O; Gabriele, B; Giulia, C; Mario, P; Nadia, C; Sara, G	1
Hatake, K; Terui, Y; Yokoyama, M	1
Jin, F; Joshi, I; Smith, MR	1
Friedberg, JW; Hagemeister, FB; Leonard, JP; Levine, AM	1

Reviews

23 review(s) available for pyrazines and Diffuse Mixed Small and Large Cell Lymphoma

Article	Year
Boron chemicals in diagnosis and therapeutics. Future medicinal chemistry, 2013, Volume: 5, Issue:6 Topics: Boron Compounds; Boron Neutron Capture Therapy; Boronic Acids; Bortezomib; Fluorescent Dyes; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species	2013
[Molecular target therapy for non-Hodgkin lymphoma]. Nihon rinsho. Japanese journal of clinical medicine, 2014, Volume: 72, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Pyrazines; Rituximab; Signal Transduction	2014
Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:16 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Inhibitors; Pyrazines	2014
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation. Leukemia & lymphoma, 2008, Volume: 49 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines; Thalidomide	2008
Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas. The oncologist, 2009, Volume: 14, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Clinical Trials as Topic; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Lymphoma, Non-Hodgkin; Oligonucleotides, Antisense; Proteasome Inhibitors; Protein Kinase C; Pyrazines; Sirolimus	2009
The spectrum of kidney involvement in lymphoma: a case report and review of the literature. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2010, Volume: 56, Issue:6 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Kidney; Lymphoma, Non-Hodgkin; Male; Prognosis; Pyrazines; Renal Insufficiency; Rituximab; Treatment Outcome	2010
Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice. Journal of the National Comprehensive Cancer Network : JNCCN, 2010, Volume: 8 Suppl 6 Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Rituximab; Thalidomide	2010
[Malignant lymphoma: individualized treatment according to biological and clinical risk factors]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:14 Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ki-1 Antigen; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Precision Medicine; Prognosis; Pyrazines; Risk Factors; Rituximab; Survival Rate; Waldenstrom Macroglobulinemia	2011
Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. The oncologist, 2012, Volume: 17, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Translational Research, Biomedical	2012
Hematologic malignancies: new developments and future treatments. Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13 Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides	2002
Update on the proteasome inhibitor bortezomib in hematologic malignancies. Clinical lymphoma, 2004, Volume: 4, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Death; Clinical Trials as Topic; Cysteine Endopeptidases; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Models, Biological; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines	2004
The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas. Current treatment options in oncology, 2004, Volume: 5, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines; Risk Assessment; Survival Rate	2004
Discovery, Development, and clinical applications of bortezomib. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors	2004
Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors	2004
Proteasome inhibitors as therapeutics. Essays in biochemistry, 2005, Volume: 41 Topics: Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines	2005
[Bortezomib]. Deutsche medizinische Wochenschrift (1946), 2006, Feb-03, Volume: 131, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Humans; Kidney Neoplasms; Leukemia; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Pyrazines	2006
Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. International journal of cancer, 2006, Sep-01, Volume: 119, Issue:5 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Synergism; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome	2006
Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2006, Volume: 20, Issue:1 Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines	2006
Fourth biannual report of the Cochrane Haematological Malignancies Group. Journal of the National Cancer Institute, 2006, Apr-19, Volume: 98, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine	2006
Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert review of anticancer therapy, 2006, Volume: 6, Issue:7 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma; Pyrazines; Waldenstrom Macroglobulinemia	2006
Proteasome inhibitors: antitumor effects and beyond. Leukemia, 2007, Volume: 21, Issue:1 Topics: Boronic Acids; Bortezomib; Cardiovascular Diseases; Dendritic Cells; Graft vs Host Disease; Humans; Lymphocytes; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction	2007
[Recent progress in rituximab therapy and its resistance--how do we overcome?]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CD55 Antigens; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Lymphoma, Non-Hodgkin; Point Mutation; Prednisone; Pyrazines; Rituximab; Vincristine	2007
Combination treatment approaches and novel therapies for lymphoma. Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:8 Suppl 12 Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cancer Vaccines; Cytokines; Humans; Immunologic Factors; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Stem Cell Transplantation	2007

Trials

15 trial(s) available for pyrazines and Diffuse Mixed Small and Large Cell Lymphoma

Article	Year
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous	2014
Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. British journal of haematology, 2014, Volume: 166, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome	2014
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood, 2016, 05-19, Volume: 127, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Cytokines; Early Termination of Clinical Trials; Female; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Pneumonia; Protein Kinase Inhibitors; Purines; Pyrazines; Quinazolinones; Salvage Therapy; Syk Kinase	2016
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clinical pharmacokinetics, 2009, Volume: 48, Issue:3 Topics: Aged; Anti-Ulcer Agents; Antineoplastic Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Boronic Acids; Bortezomib; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Omeprazole; Proton Pump Inhibitors; Pyrazines	2009
Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma. Leukemia & lymphoma, 2010, Volume: 51, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cohort Studies; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome	2010
Ligustrazine as a salvage agent for patients with relapsed or refractory non-Hodgkin's lymphoma. Chinese medical journal, 2010, Volume: 123, Issue:22 Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pyrazines; Treatment Outcome; Young Adult	2010
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8 Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome	2011
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. American journal of hematology, 2011, Volume: 86, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Child; Cyclams; Europe; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous	2011
Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma. Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Grading; Pyrazines; Rituximab; Treatment Outcome	2012
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. Clinical pharmacokinetics, 2011, Dec-01, Volume: 50, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Cytochrome P-450 CYP3A; Dexamethasone; Drug Combinations; Enzyme Induction; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Rifampin	2011
Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma. British journal of haematology, 2012, Volume: 158, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Proteins; Protein Array Analysis; Pyrazines; Recurrence; Treatment Outcome	2012
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. Leukemia & lymphoma, 2013, Volume: 54, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Pyrazines; Radioimmunotherapy; Recurrence; Treatment Outcome; Yttrium Radioisotopes	2013
New developments with bortezomib in treating multiple myeloma. Clinical lymphoma, 2004, Volume: 4, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Division; Doxorubicin; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Liposomes; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Renal Insufficiency; Treatment Outcome	2004
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Protease Inhibitors; Pyrazines	2005
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? British journal of haematology, 2006, Volume: 134, Issue:4 Topics: Aged; Boronic Acids; Bortezomib; Drug Hypersensitivity; Female; Humans; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Protease Inhibitors; Pyrazines; Skin; Skin Diseases, Vascular; Treatment Outcome	2006

Other Studies

20 other study(ies) available for pyrazines and Diffuse Mixed Small and Large Cell Lymphoma

Article	Year
2019 ASH Annual Meeting. The Lancet. Haematology, 2020, Volume: 7, Issue:1 Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pyrazines	2020
CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. European journal of haematology, 2014, Volume: 93, Issue:1 Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pyrazines; Rituximab	2014
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma. Journal of the National Cancer Institute, 2014, Volume: 106, Issue:8 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine	2014
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vincristine	2008
PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, May-15, Volume: 15, Issue:10 Topics: Aged; Antineoplastic Agents; Apoptosis; Benzofurans; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma; Lymphoma, Non-Hodgkin; Male; Membrane Potential, Mitochondrial; Middle Aged; NF-kappa B; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured	2009
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II. Journal of the National Comprehensive Cancer Network : JNCCN, 2004, Volume: 2 Suppl 4 Topics: Boronic Acids; Bortezomib; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Protease Inhibitors; Proteasome Inhibitors; Pyrazines	2004
Continual reassessment method with multiple toxicity constraints. Biostatistics (Oxford, England), 2011, Volume: 12, Issue:2 Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Clinical Trials, Phase I as Topic; Computer Simulation; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epidemiologic Research Design; Humans; Lymphoma, Non-Hodgkin; Maximum Tolerated Dose; Models, Statistical; Neoplasms; Neurotoxicity Syndromes; Prednisolone; Probability; Pyrazines; Statistical Distributions; Thrombocytopenia; Vincristine	2011
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Experimental hematology, 2011, Volume: 39, Issue:10 Topics: Acetylation; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Hodgkin Disease; Humans; Indoles; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Processing, Post-Translational; Pyrazines; Pyridines; Pyrroles; Sulfonamides; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein	2011
Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells. Cancer science, 2012, Volume: 103, Issue:2 Topics: Adolescent; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line; Cell Survival; Child; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Pyrazines; T-Lymphocytes; Valproic Acid	2012
New agents for the treatment of lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Immunotoxins; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Proteasome Inhibitors; Pyrazines	2012
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. Hematological oncology, 2013, Volume: 31, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Off-Label Use; Peripheral Nervous System Diseases; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Rituximab; Signal Transduction; Transplantation, Autologous; Treatment Outcome	2013
Innovative strategies in lymphoma therapy. Wiener klinische Wochenschrift, 2003, Aug-14, Volume: 115, Issue:13-14 Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Forecasting; Genetic Therapy; Humans; Immunoconjugates; Immunotherapy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Prednisone; Protease Inhibitors; Proteomics; Pyrazines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Rituximab; Signal Transduction; Survival Analysis; Thalidomide; Time Factors; Vincristine	2003
Proteasome inhibition therapy: assessing the clinical implications in hematologic diseases. ONS news, 2004, Volume: 19, Issue:9 Suppl Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nursing Assessment; Oncology Nursing; Protease Inhibitors; Proteasome Inhibitors; Pyrazines	2004
The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer biology & therapy, 2005, Volume: 4, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Herpesviridae Infections; Herpesvirus 8, Human; Humans; Lymphoma, Non-Hodgkin; Pyrazines; Tumor Cells, Cultured	2005
Proteasome inhibitors in non-Hodgkin's lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN, 2005, Volume: 3 Suppl 1 Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines	2005
The ubiquitin proteasome pathway from bench to bedside. Hematology. American Society of Hematology. Education Program, 2005 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin	2005
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:5 Topics: Aged; Boronic Acids; Bortezomib; Electrodiagnosis; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Nervous System Diseases; Prostatic Neoplasms; Protease Inhibitors; Pyrazines	2006
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. American journal of hematology, 2007, Volume: 82, Issue:5 Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chickenpox; Dexamethasone; Disease Susceptibility; Doxorubicin; Female; Herpesvirus 3, Human; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Virus Activation	2007
Unexpected cardiotoxicity in haematological bortezomib treated patients. British journal of haematology, 2007, Volume: 138, Issue:3 Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Heart Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines	2007
Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-15, Volume: 13, Issue:18 Pt 2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 9; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Phosphorylation; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha	2007